Clinical Trials Logo

Borderline Personality Disorder clinical trials

View clinical trials related to Borderline Personality Disorder.

Filter by:

NCT ID: NCT00254748 Completed - Clinical trials for Borderline Personality Disorder

Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients

Start date: June 2004
Phase: Phase 2
Study type: Interventional

In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well designed controlled studies have been performed on the effect of one of the newer atypical antipsychotics on psychotic symptoms. It is of interest to investigate the benefit of quetiapine treatment in these types of patients. Quetiapine possibly gives less side-effects because of the expected lack of elevated prolactin levels, which is of importance in this patient group, overrepresented by young females. In this double blind, randomized, placebo controlled, 8 week, parallel group, multi-center study, quetiapine (in flexible doses between 200 mg/day and 600 mg/day) will be compared with the placebo.

NCT ID: NCT00252031 Recruiting - Clinical trials for Borderline Personality Disorder

DBT in Borderline Personality Disorder

Start date: n/a
Phase: N/A
Study type: Interventional

Subjects will receive a 6-month course of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist.

NCT ID: NCT00247234 Completed - Clinical trials for Personality Disorder, Borderline

Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders

Start date: September 2004
Phase: N/A
Study type: Interventional

This study intends to compare the effectiveness of schema therapy with standard psychiatric outpatient care for patients with borderline or avoidant personality disorder.

NCT ID: NCT00222482 Completed - Clinical trials for Borderline Personality Disorder

Depakote ER in Borderline Personality Disorder

Start date: March 2003
Phase: N/A
Study type: Interventional

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

NCT ID: NCT00204347 Completed - Clinical trials for Borderline Personality Disorder

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

Start date: July 2003
Phase: Phase 4
Study type: Interventional

The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings, impulsivity, thing difficulties and disturbed relationships. The secondary objective of this study (Study B)is to validate a self-report measure of clinical symptoms specific to the treatment of patients with BPD, the UAB Borderline Rating Scale(BRS).

NCT ID: NCT00202215 Completed - Eating Disorders Clinical Trials

Chrysalis Day Program Body Mass Index Study

Start date: October 2001
Phase: N/A
Study type: Interventional

This is a study to determine if the approach taken to treat patients in the Chrysalis Day Hospital Program will favourably effect their health status as assessed by Body Mass Index (BMI)

NCT ID: NCT00202202 Completed - Clinical trials for Borderline Personality Disorder

User Satisfaction Survey - Personality Disorder Service

Start date: November 2002
Phase: N/A
Study type: Interventional

Can we improve our community partners satisfaction with a change in how psychiatric consultations are delivered to their clients by our psychiatrist? This survey of users of the service will compare the level of satisfaction before(retrospectively) to after the way the service is provided is changed.

NCT ID: NCT00183651 Completed - Suicide Clinical Trials

Treatment of Suicidal Women With Borderline Personality Disorder

Start date: April 2004
Phase: Phase 2
Study type: Interventional

This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.

NCT ID: NCT00178061 Completed - Clinical trials for Borderline Personality Disorder

Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder

Start date: August 1997
Phase: Phase 4
Study type: Interventional

This study will examine the impact of comorbid personality disorder on the outcome of treatment among patients with bipolar I disorder.

NCT ID: NCT00154154 Completed - Clinical trials for Borderline Personality Disorder

Hope for the Chronically Suicidal Patient

Start date: October 2002
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the clinical and cost effectiveness of Dialectical Behavior Therapy (DBT) for chronically suicidal behavior in individuals diagnosed with borderline personality disorder (BPD). Recent investigations of DBT have yielded positive results and have challenged the widely held opinion that the prognosis for this condition is poor. This study will consist of a two-arm randomized controlled trial that will compare DBT with a General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling. One-hundred and eighty participants will be randomly assigned to either DBT or to the GPM condition. Clinical outcomes will be assessed by changes in: (1) parasuicidal behaviour; (2) treatment retention; (3) psychiatric symptomatology; (4) anger expression; (5) social functioning and (6) health status. Cost outcomes will include an analysis of health service utilization. Clinical and cost evaluations will occur at 4-month intervals over the course of the one-year treatment and over a two-year follow-up.